Patients with laryngopharyngeal reflux (LPR) undergoing treatment appear to have improvement in symptoms before the complete resolution of the laryngeal findings. Objective: To determine whether patients with LPR experience an improvement in symptoms before the complete resolution of the laryngeal findings. Methodology: Forty consecutive patients with LPR documented by double-probe pH monitoring were evaluated prospectively. Symptom response to therapy with proton pump inhibitors was assessed at 2, 4, and 6 months of treatment with a selfadministered reflux symptom index (RSI). In addition, transnasal fiberoptic laryngoscopy (TFL) was performed and a reflux finding score (RFS) was determined for each patient at each visit. Results: The mean RSI at entry was 19.3 (؎ 8.9 standard deviation) and it improved to 13.9 (؎ 8.8) at 2 months of treatment (P <.05). No further significant improvement was noted at 4 months (13.1 ؎ 9.8) or 6 months (12.2 ؎ 8.1) of treatment. The RFS at entry was 11.5 (؎ 5.2), and it improved to 9.4 (؎ 4.7) at 2 months, 7.3 (؎ 5.5) at 4 months, and 6.1 (؎ 5.2) after 6 months of treatment (P <.05 with trend). Conclusions: Symptoms of LPR improve over 2 months of therapy. No significant improvement in symptoms occurs after 2 months. This preliminary report demonstrates that the physical findings of LPR resolve more slowly than the symptoms and this continues throughout at least 6 months of treatment. These data imply that the physical findings of LPR are not always associated with patient symptoms, and that treatment should continue for a minimum of 6 months or until complete resolution of the physical findings.
INTRODUCTION
Laryngopharyngeal reflux (LPR) is common in otolaryngologic practice. The prevalence of reflux in patients with voice disorders may be as high as 50%.
1 reflux symptoms include hoarseness, cough, vocal fatigue, globus, excessive throat clearing, dysphonia, and mild dysphagia. We have developed a nine-item, 45-point scale to document the severity of patient symptoms of LPR. The laryngeal physical findings of uncomplicated LPR include edema, posterior glottic erythema, and mucosal hypertrophy. We have recently validated a weighted, eight-item, 26-point LPR physical finding score to document laryngeal reflux findings. 2 Even though LPR is common, its diagnosis may be difficult, because its symptoms are nonspecific and the laryngeal findings are not always associated with symptom severity. The purpose of this investigation was to evaluate the association between the symptoms and physical findings of patients with LPR.
MATERIALS AND METHODS
Forty consecutive patients with a diagnosis of uncomplicated LPR as confirmed by 24-hour double-probe (simultaneous esophageal and pharyngeal) pH monitoring were enrolled. Uncomplicated LPR was defined as a pharyngeal reflux event of pH less than or equal to 4 without any evidence of glottic/subglottic stenosis, carcinoma, leukoplakia, paradoxic vocal fold motion, or granuloma formation. All patients were treated with twice-daily proton pump inhibitors (PPI-20 mg omeprazole, 30 mg lansoprazole, or 20 mg rabeprazole). Patients were reevaluated at 2, 4, and 6 months of therapy.
A self-administered reflux symptom index (RSI) was completed by each subject at every visit (Table I) . Each of the items is related to LPR and is scored from 0 (no problem) to 5 (severe problem). The RSI has been used at the Center for Voice Disorders of Wake Forest University, Winston-Salem, NC, for many years and has allowed documentation of patient treatment outcomes. A comprehensive head and neck examination, including transnasal fiberoptic laryngoscopy (TFL) with photographdocumentation and determination of the reflux finding score (Table II), was also performed by an otolaryngologist at study entry and at each follow-up visit.
All data were coded and entered into SPSS 6. 
RESULTS
Forty consecutive patients with pH probedocumented LPR were enrolled. One person was excluded because of incomplete data. Twenty-six percent (10 of 39) were male. The mean age of the cohort was 50 years.
The RSI ranges from a lowest (asymptomatic) possible score of 0 to a highest possible score of 45. The mean symptom index at entry was 19.3 (Ϯ 8.9 standard deviation). It improved significantly to 13.9 (Ϯ 8.8) at 2 months of treatment (P Ͻ.05). No further improvement was noted at 4 months (13.1 Ϯ 9.8) or at 6 months (12.2 Ϯ 8.1) of therapy (P Ͼ.05).
The reflux finding score (RFS) ranges from a lowest possible score of 0 (normal larynx) to a worst possible score of 26. The mean pretreatment RFS was 11.5 (Ϯ 5.2 standard deviation). Significant improvement in the RFS was noted at 2 months (9.4 Ϯ 4.7), at 4 months (7.3 Ϯ 5.5), and at 6 months (6.1 Ϯ 5.2) of therapy (P Ͻ.05 with trend).
DISCUSSION
Symptom resolution of uncomplicated LPR occurs over 2 months of therapy with proton pump inhibitors. However, the physical findings of LPR improve more slowly and continue to get better throughout at least 6 months of treatment. A 19% reduction in physical findings was noted at 2 months, a 37% reduction was noted at 4 months, and a 47% reduction was noted at the completion of this preliminary 6-month study period.
Voice disorders are often multifactorial. Therefore, the inability of proton pump inhibitors to completely resolve the symptoms or physical findings (RSI and RFS ϭ 0) is expected. At our institution, we do not consider an RSI of Ͻ10 or a RFS of Ͻ5 to be clinically significant. These numbers are based on preliminary data of symptoms and occult laryngeal pathology in a community cohort. 3 Treatment of LPR for more than 6 months may be indicated to achieve a complete resolution of physical findings (RFS Ͻ5) and to avoid the possible return of symptoms. Cessation of therapy based on an improvement of LPR symptoms alone may be premature. This conclusion is consistent with the opinion of the Consensus Conference Report on LPR (1997) that recommended twice-daily proton pump inhibitor treatment be continued for a minimum period of 6 months. 4 Longer-term therapy was not addressed in this study. However, in our experience, lifelong therapy with proton pump inhibitors or a fundoplication is necessary in some patients. This prolonged length of treatment differs from that of gastroenterology patients with reflux esophagitis for various reasons.
Clinical evidence suggests that LPR is different from classic gastroesophageal reflux disease (GERD) as seen in gastroenterology patients with heartburn (esophagitis). In fact, patients with LPR frequently do not have either esophagitis or heartburn. This is because the majority of individuals with LPR have normal esophageal acid clearance, which is a good overall indicator of esophageal motor function. Therefore, in many individuals with LPR, the amount of acid in the esophagus is well under the established laboratory normative data for the diagnosis of gastroesophageal reflux. This so-called "physiological reflux" does not normally result in symptoms such as heartburn. The larynx itself does not appear to respond well to chemical trauma as a result of the fact that the mucosa of the larynx is thin, fragile, and poorly adapted to protect against acid and activated pepsin. The laryngopharynx is also devoid of the acid clearance mechanisms found in the esophagus and is therefore far more susceptible to peptic injury. [5] [6] [7] Symptomatic relief for gastroenterology patients with GERD can often be obtained with behavioral modification, antacids, and/or over-the-counter histamine-2-receptor antagonists. 8 Such treatment, however, fails to control extra-esophageal reflux in the majority of otolaryngology patients with LPR. 6 In our experience, it appears that therapy with proton pump inhibitors is necessary for the resolution of the laryngeal symptoms and physical findings of patients with LPR. In addition to the type of treatment, the dosage and length of treatment is also of concern. A significant proportion of patients on twice-daily proton pump inhibitors do not have adequate acid suppression for healing of LPR. 9, 10 Thus, up to 40% of LPR patients may require higher doses or a fundoplication for resolution to occur. In regard to the length of treatment, the results of the present study support the recommendations of the Consensus Conference Report on LPR that empiric treatment should be continued for a minimum of 6 months in most cases. This suggestion differs from the current recommendations in the gastroenterology literature that suggest therapy should be stopped after 2 to 3 months. 11 These recommendations, however, are based on patient symptoms and not laryngeal findings. The results of this investigation suggest that 2 to 3 months of therapy would often be insufficient to reverse the tissue injury of the larynx.
CONCLUSION
The improvement of patient symptoms with LPR occurs over 2 months of therapy with twice-daily proton pump inhibitors (PPI). The resolution of laryngeal findings, however, takes longer and continues throughout at least 6 months of treatment. The results of our investigation suggest that the initial treatment of most patients with uncomplicated LPR should include twice-daily PPI therapy and behavioral modification. The percentage of relative drug resistance with twice-daily PPI may be as high as 40%, and a low threshold for increasing the dosage to three or four times a day, or changing to a different PPI, should be maintained. 10 Patient symptoms can be expected to improve by 2 months, although therapy should continue at least until the resolution of laryngeal findings which may take up to 6 months or longer.
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